AARD

$5.55+$0.42 (+8.19%)prev close

Compare

Change$-8.76

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held · Bookmarked

0 · 0

portfolios · users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$112.3M

22M shares

52-week range

$3.35 – $17.94

15% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

P/E LTM (FWD)

— (6.4)

Run the fair-value model →

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$300000	—	$-3.15	$-3.80–$-2.46	—	9
2027	$1M	+242.0%	$-2.56	$-3.62–$-1.84	—	9
2028	$7M	+543.1%	$-2.47	$-4.13–$-1.10	—	7
2029	$104M	+1482.0%	$-1.49	$-1.49–$-1.49	—	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.87	$-0.66	+24.5%
2026-05-07	$-0.88	$-0.99	-12.9%
2026-03-23	$-0.83	$-0.81	+2.1%
2025-11-13	$-0.80	$-0.75	+6.1%
2025-08-13	$-0.60	$-0.66	-10.0%
2025-05-14	$-0.67	$-0.71	-5.4%
2025-03-31	$-0.41	$-0.43	-6.1%

DCF fair valuemodel estimate

Intrinsic value

$2.06

Price

$5.55

Implied downside

-63%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
AARDAardvark Therapeutics, Inc. Common Stock	$5.55	+8.19%	$121M	—
ASMBAssembly Biosciences, Inc.	$28.96	-2.82%	$574M	—
AVTXAvalo Therapeutics, Inc.	$16.18	+0.37%	$851M	—
CRBUCaribou Biosciences, Inc.	$1.29	+1.57%	$128M	—
ENTAEnanta Pharmaceuticals, Inc.	$13.12

Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

www.aardvarktherapeutics.com

Employees: 28
IPO / List date: Feb 13, 2025
HQ: SAN DIEGO, CA

Held by traders on TradeandTell

No one on the platform currently holds AARD.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	70,792	$266.9K

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2008-07-21	1-for-2reverse

Recent trades on TradeandTell

No one on the platform has traded AARD yet.

$AARD chatter on StockTwits

jorge .miguel@focafoca99Aug 27
$AARD alerts investors to a securities class action alleging false safety claims for ARD-101.
View on StockTwits ↗
jorge .miguel@focafoca99Aug 25
$AARD files a securities class action notice for investors to seek recovery.
View on StockTwits ↗
11th.com@11thestateAug 24
In the end, $AARD investors were left with the stock down more than 70% across two major disclosures and stuck with their losses. Here’s an update worth your attention: a new case was recently filed against Aardvark Therapeutics over claims that the company overstated the safety of its lead drug ARD-101, including calling it “well-tolerated” while allegedly concealing cardiac safety risks. Check out the latest case updates and learn how to join the case here: https://11th.com/cases/aardvarktherapeutics-investor-suit
View on StockTwits ↗
L G@LivermoresGhostBullishAug 22
$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!!! https://www.compuserve.com/pf/story/0022/20260817/9811028.htm $PSQH $ISOU $NINE $AARD
View on StockTwits ↗
Sanford Webb@BiotechnicityBullishAug 20
$AARD Don’t hold a position here but want to voice a minority opinion holding that SAE’s in healthy subjects is Bullsh*t given that already compromised Prader-Willi patients might not experience the same response. It’s entirely possible that patients with already compromised CVS may, in fact, respond differently. I’m well aware of the historical precedent of caution with respect to healthy patients but scraping a study on that axiom alone seems precipitous. Aardvark will launch the Phase-3 again.
View on StockTwits ↗
jorge .miguel@focafoca99Aug 17
$AARD announced a securities class-action deadline for investors on Oct 13.
View on StockTwits ↗
MoneyFairyBlessings@MoneyFairyBlessingsBullishAug 11
$AARD Very bullish here. The volume is impressive considering it does not normally have any volume.
View on StockTwits ↗
5,500% ROI this quarter@55X_ROI_Q1_2026Aug 2
$AARD $SLS @jfais is a pos short scumbag. $XBI said to sell SlS short +400% ago. "Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company's lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein," stated Dr. Weber. "I am excited to join the other scientists on the Company's SAB and offer the insights that I have in the area of oncoimmunology research and development.
View on StockTwits ↗
S Lucky@SmartLuckyAug 1
$AARD $SLS
View on StockTwits ↗
Easy E@EddieH2020BullishAug 1
$SLS Here is the link for handy reference as we go up: https://stocktwits.com/JFais/message/634612371 SLS is gonna send you and Seedy back to Peru 🤣 @OnTheBalance 😋 $XBI $SPY
View on StockTwits ↗
Jacob Mihnovski@YashinvestJul 28
$AARD Daily chart, price doubling potential
View on StockTwits ↗
Jumanah Oamr@jumanah1212BullishJul 27
$AARD head and shoulders 💸💸🚀🚀🚀🚀
View on StockTwits ↗
Jumanah Oamr@jumanah1212BullishJul 23
$AARD Double Bottom pattern: Suggests a potential bullish reversal (strong support at the two bottoms) Nearby resistance: $7.90, $10.00💸💸🚀🚀
View on StockTwits ↗
Legacy Trader@StockScannersJul 14
$AARD reached 7.92
View on StockTwits ↗
AfterHour King@ReesiferBullishJul 13
$AARD added 5.95
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.